Print Page   |   Contact Us   |   Your Cart   |   Sign In
Sign In

Forgot your password?

Haven't registered yet?

Breaking News
News & Press: Daily Updates

NIH begins testing investigational Zika vaccine in humans

Wednesday, August 03, 2016   (0 Comments)

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has launched a clinical trial of a vaccine candidate intended to prevent Zika virus infection. The early-stage study will evaluate the experimental vaccine’s safety and ability to generate an immune system response in participants. At least 80 healthy volunteers ages 18-35 years at three study sites in the United States, including the NIH Clinical Center in Bethesda, Maryland, are expected to participate in the trial. Scientists at NIAID’s Vaccine Research Center (VRC) developed the investigational vaccine — called the NIAID Zika virus investigational DNA vaccine — earlier this year.


OSAP Disclaimer | Please notify our webmaster of any problems with this website.
OSAP thanks its Super Sponsors for their support in 2016. Sponsorship does not imply endorsement by OSAP of a company's products or services.